Advances in proteomics in diffuse large B‑cell lymphoma (Review)

Abstract

Diffuse large B‑cell lymphoma (DLBCL) is the most common pathological type of non‑Hodgkin's lymphoma. Although the development of monoclonal antibodies, small‑mole‑ cule‑targeted drugs and novel chemotherapeutic agents, and the increased use of immunotherapy have markedly improved the outcomes of DLBCL, ~40% of patients cannot be cured following the use of standardized first‑line treatment. In addi‑ tion, the specific mechanisms of drug resistance and potential factors associated with a poor prognosis in these patients remain unclear. Proteomics research is used to determine potential asso‑ ciations between changes in DLBCL protein expression levels and different stages of disease occurrence and development. Proteomics may aid in the identification of novel molecular mechanisms and drug resistance mechanisms, through iden‑ tifying multiple associated proteins and monitoring changes in expression levels. Thus, proteomics research may exhibit poten‑ tial in the development of therapeutic targets and in improving prognostic evaluation in patients with DLBCL. The present study aimed to review the use of proteomic methods for the investiga‑ tion of DLBCL, including the mechanisms underlying disease progression and drug resistance in DLBCL, and the function of the tumor microenvironment in lymphoma growth. The present review also demonstrated the potential of proteomic‑guided therapeutic strategies for DLBCL and discussed the synergistic benefits of using proteomic methods in DLBCL research.